<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580537</url>
  </required_header>
  <id_info>
    <org_study_id>LAsED</org_study_id>
    <secondary_id>2019-002960-29</secondary_id>
    <secondary_id>H-19047222</secondary_id>
    <nct_id>NCT04580537</nct_id>
  </id_info>
  <brief_title>Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails</brief_title>
  <acronym>LAsED</acronym>
  <official_title>Assessing the Efficacy of Image-guided Laser-assisted Enstilar® Delivery for Treatment of Psoriatic Nails - a Proof-of-concept, Single-center, Prospective, Open-label, Randomized, Clinical Trial With an Intra-individual Comparison of Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LEO Innovation Lab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is conducted to investigate the clinical efficacy of a combination product&#xD;
      containing calcipotriol and betamethasone formulated as an aerosol foam (Enstilar ©) for the&#xD;
      treatment of nail psoriasis in conjunction with physical pre-treatment using a fractionally&#xD;
      ablative carbon dioxide laser (AFL). It is hypothesized, based on preclinical data and&#xD;
      comparable clinical trials, that laser processing prior to topical administration will lead&#xD;
      to increased drug distribution, and thereby increase the efficacy of Enstilar® in treating&#xD;
      nail psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>a proof-of-concept, single-center, prospective, open-label, randomized, clinical trial with an intra-individual comparison of treatments</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of topical delivery of Enstilar® with and without laser pre-treatment to improve nail psoriasis</measure>
    <time_frame>Day1 : Week 24</time_frame>
    <description>Change from baseline to end of treatment in N-NAIL score per nail for each treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety profile and local tissue response to laser treatment and Enstilar® application</measure>
    <time_frame>Day 1 : Week 24</time_frame>
    <description>Number of laser- and Enstilar®- emergent adverse events per subject; change in local tissue response score from baseline to Week 12 and Week 24.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Nail Psoriasis</condition>
  <arm_group>
    <arm_group_label>Laser-assisted Enstilar delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ablative fractional laser (AFL) pre-treatment + daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enstilar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Daily use of Enstilar (cutaneous foam: 0.5 mg/g betamethasone dipropionate, 0.05mg/g calcipotriol)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enstilar</intervention_name>
    <description>Daily application on affected fingers (nail plates, nail folds, and surrounding skin)</description>
    <arm_group_label>Enstilar</arm_group_label>
    <arm_group_label>Laser-assisted Enstilar delivery</arm_group_label>
    <other_name>Cutaneous foam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablative fractional laser</intervention_name>
    <description>Pre-treatment of affected fingers (nail plates, nail folds)</description>
    <arm_group_label>Laser-assisted Enstilar delivery</arm_group_label>
    <other_name>AFL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Informed consent obtained before any trial-related activities.&#xD;
&#xD;
          2. At least 18 years of age (inclusive)&#xD;
&#xD;
          3. Confirmed diagnosis of psoriatic disease with signs of nail psoriasis on at least 2&#xD;
             digits&#xD;
&#xD;
          4. Minimum nail involvement as assessed by treating physician (N-NAIL score of ≥ 2 for at&#xD;
             least two individual nails)&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Insufficient knowledge of written and spoken Danish.&#xD;
&#xD;
          2. Pregnant and lactating women and women who intend to become pregnant during the trial&#xD;
&#xD;
          3. Pre-existing clinical manifestations of long-term side effects of corticosteroid use&#xD;
             including but not limited to skin atrophy or telangiectasias on fingers&#xD;
&#xD;
          4. Presence of any skin condition or coloration (marked suntan, hyperpigmentation,&#xD;
             smoking-induced staining, tattoos or body art) that would interfere with the&#xD;
             evaluation of the clinical response in the test sites or assessment&#xD;
&#xD;
          5. Any non-psoriatic disease activity within test areas&#xD;
&#xD;
          6. Significant history or current evidence of chronic infectious disease, systemic&#xD;
             disorders, or organ dysfunction where the use of Enstilar is contraindicated.&#xD;
&#xD;
          7. Known predisposition for hypertrophic scar formation.&#xD;
&#xD;
          8. Known allergy to any of the components of Enstilar®.&#xD;
&#xD;
          9. Current treatment with systemically or locally acting medications which might counter&#xD;
             or influence the trial aim&#xD;
&#xD;
         10. Received any drug as part of a research trial within 30 days prior to initial trial&#xD;
             dosing.&#xD;
&#xD;
         11. Artificial nail enhancement or damages associated with it, including (semi-) permanent&#xD;
             nail polish e.g. acrylic based gels.&#xD;
&#xD;
         12. Ongoing fungal infections of psoriatic nails&#xD;
&#xD;
         13. Close affiliation with the investigator (e.g. a close relative) or persons working at&#xD;
             the respective trial site or the participant is an employee of the sponsor&#xD;
&#xD;
         14. In the opinion of the investigator, the participant is unlikely to comply with the&#xD;
             Clinical Trial Protocol (e.g. alcoholism, drug dependency or psychotic state).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merete Haedersdal, MD PhD DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vinzent K Ortner, MD</last_name>
    <phone>+45 52177729</phone>
    <email>vinzent.kevin.ortner@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital Region</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinzent K Ortner, MD</last_name>
      <email>vinzent.kevin.ortner@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 2, 2020</last_update_submitted>
  <last_update_submitted_qc>October 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Merete Haedersdal</investigator_full_name>
    <investigator_title>Sponsor-Investigator [Consultant in dermatology, Clinical professor]</investigator_title>
  </responsible_party>
  <keyword>Nail disease</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>Laser-assisted drug delivery</keyword>
  <keyword>Enstilar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

